GNH USA

Europe — EMA

Octreoscan (Indium In-111 Pentetreotide)

GNH USA supplies Octreoscan (Indium In-111 Pentetreotide), a radiopharmaceutical for neuroendocrine tumor imaging. Request a quote for global supply.

Indium In-111 Pentetreotide

Request sourcing

1
Pack/s

What is Indium In-111 Pentetreotide?

Indium In-111 Pentetreotide, the active ingredient in Octreoscan, is a radiopharmaceutical presented as a diagnostic imaging agent for intravenous use. It binds to somatostatin receptors, enabling visualization of neuroendocrine tumors and related lesions in adult patients. GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Indium In-111 Pentetreotide used for?

Octreoscan is employed in the diagnostic pathway for somatostatin‑receptor positive neuroendocrine tumors. It helps clinicians locate and stage disease. - Neuroendocrine tumor imaging: Improves detection and anatomical mapping of primary and metastatic lesions. - Gastroenteropancreatic tumor assessment: Assists in evaluating tumor burden and treatment planning. - Carcinoid syndrome evaluation: Supports identification of occult disease sites contributing to hormonal symptoms.

What are the side effects of Indium In-111 Pentetreotide?

Adverse reactions are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common Side Effects: - Nausea: Mild to moderate nausea reported in some patients. - Flushing: Transient facial or upper‑body flushing. - Injection site pain: Discomfort at the site of intravenous administration. - Headache: Mild headache occurring shortly after injection.

Serious or Rare Side Effects: - Hypersensitivity reaction: Rash, urticaria, or anaphylaxis. - Severe hypotension: Marked drop in blood pressure post‑injection. - Bone marrow suppression: Transient reductions in blood cell counts. - Renal toxicity: Rare impairment of kidney function.

What precautions apply to Indium In-111 Pentetreotide?

Before using Octreoscan, clinicians should evaluate patient suitability and monitor for potential adverse events. - Pregnancy testing: Perform before administration in women of childbearing potential. - Breastfeeding: Advise discontinuation during the imaging period. - Renal function: Assess baseline kidney function as the agent is renally excreted. - Prior radiation exposure: Consider cumulative dose from previous radiopharmaceuticals. - Store at ambient temperature: Keep in original container, protect from light and moisture.

What does Indium In-111 Pentetreotide interact with?

Octreoscan may interact with other agents that affect radiation exposure or renal clearance.

Major Interactions (Avoid): - Concurrent radiopharmaceutical therapy: Increases cumulative radiation dose. - Nephrotoxic drugs: May exacerbate renal clearance issues.

Moderate Interactions (Monitor Closely): - Diuretics: Can alter renal excretion rate. - ACE inhibitors: May affect blood pressure response post‑injection. - Antihistamines: May mask early signs of hypersensitivity. - Contrast agents: Potential additive radiation exposure during imaging. - Chemotherapy agents: Overlap in bone‑marrow suppression risk.

Frequently asked questions

What is Octreoscan used for?+
Octreoscan is a radiopharmaceutical used primarily to locate and stage somatostatin‑receptor positive neuroendocrine tumors. It provides whole‑body imaging that helps physicians assess tumor spread, plan surgery or other therapies, and monitor disease progression.
How does Indium In-111 Pentetreotide work?+
Indium In-111 Pentetreotide is a somatostatin analogue that binds to somatostatin receptors on neuroendocrine tumor cells. The attached indium‑111 emits gamma radiation, which is captured by a gamma camera to produce detailed images of receptor‑bearing tissues.
What is the usual dose of Octreoscan?+
The administered activity of Octreoscan is determined by the prescribing physician based on patient weight, age, and the specific imaging protocol. Dosage is individualized and should follow local regulatory and institutional guidelines.
Is Octreoscan safe during pregnancy or breastfeeding?+
Octreoscan is generally contraindicated in pregnancy because radiation exposure may affect the fetus. Women of childbearing potential should undergo pregnancy testing, and breastfeeding should be paused during the imaging period to avoid radiation transfer to the infant.
How do I order Octreoscan from GNH USA?+
To order Octreoscan, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does Octreoscan compare with other neuroendocrine tumor imaging agents?+
Octreoscan is a gamma‑emitting agent that provides high‑resolution whole‑body imaging, whereas newer PET agents such as Ga‑68 DOTATATE offer higher sensitivity and faster imaging times. Choice of agent depends on equipment availability, regulatory approval, and specific clinical questions.
What are the storage and handling requirements for Octreoscan?+
Octreoscan should be stored at ambient temperature, protected from light, and kept in its original sealed container. Avoid exposure to moisture and handle with radiation safety precautions as recommended by local guidelines.
How is Octreoscan administered?+
Octreoscan is administered intravenously by a qualified healthcare professional. After injection, imaging is typically performed 24 hours later to allow optimal tumor uptake and clearance of background activity.
What are the most serious risks associated with Octreoscan?+
Serious risks include hypersensitivity reactions, severe hypotension, and rare bone‑marrow suppression or renal toxicity. Patients should be monitored during and after injection for any signs of adverse reactions, and emergency measures should be readily available.
Who should not receive Octreoscan?+
Octreoscan is contraindicated in patients with known hypersensitivity to the product, pregnant women, and individuals with severe renal impairment where clearance cannot be assured. Caution is also advised for patients who have recently received other radiopharmaceuticals.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Indium In-111 Pentetreotide
Route
Intravenous Use
Manufacturer
Curium Netherlands B.V.
Origin
EU

Related products

Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Belgium Bv
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU